一分钟看懂
这是一项关于结直肠癌的I 期 / II 期研究，登记的药物或干预包括Sacituzumab tirumotecan；Fluorouracil (5-FU)；Leucovorin (LV) or levoleucovorin；Rescue medication；Supportive care measures；Cisplatin；Pembroliz，当前状态为招募中。登记地点显示中国北京、福州、武汉、长沙等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sacituzumab tirumotecan；Fluorouracil (5-FU)；Leucovorin (LV) or levoleucovorin；Rescue medication；Supportive care measures；Cisplatin；Pembrolizumab · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital-Digestive Oncology ( Site 0061) · 北京
- The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Site 0063) · 福州
- Wuhan Union Hospital Cancer Center. ( Site 0064) · 武汉
- Hunan Cancer Hospital-intervention department ( Site 0066) · 长沙
- Renji Hospital Shanghai Jiao Tong University School of Medicine-Oncology Department ( Site 0067) · 上海
- West China Hospital, Sichuan University ( Site 0068) · 成都
公开的入选条件
- The main inclusion criteria include but are not limited to the following:
- * Has one of the following cancers:
- Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer
- Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer
- Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer
- Advanced and/or unresectable BTC and has not received prior therapy for the cancer
- * For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06428409；登记信息更新于 2026-09-17。